Argenica Therapeutics Limited (ASX:AGN)

Argenica Therapeutics Revenue

In the fiscal year ending June 30, 2026, Argenica Therapeutics had annual revenue of 5.48M AUD with 70.66% growth. Argenica Therapeutics had revenue of 4.86M in the half year ending June 30, 2026, with 1,878.64% growth.

• Revenue: 5.48M
• Revenue Growth: +70.66%
• P/S Ratio: 3.51
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 19.27M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	5.48M	2.27M	70.66%
Jun 30, 2025	3.21M	615.81K	23.70%
Jun 30, 2024	2.60M	848.04K	48.46%
Jun 30, 2023	1.75M	1.49M	575.38%
Jun 30, 2022	259.10K	-36.98K	-12.49%

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 17, 2026

Data Sources Report a data error